JP2016510597A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510597A5 JP2016510597A5 JP2015561743A JP2015561743A JP2016510597A5 JP 2016510597 A5 JP2016510597 A5 JP 2016510597A5 JP 2015561743 A JP2015561743 A JP 2015561743A JP 2015561743 A JP2015561743 A JP 2015561743A JP 2016510597 A5 JP2016510597 A5 JP 2016510597A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- vector
- antigen
- receptor
- specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 22
- 239000013598 vector Substances 0.000 claims 16
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 206010021143 Hypoxia Diseases 0.000 claims 8
- 230000007954 hypoxia Effects 0.000 claims 8
- 230000001105 regulatory effect Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 6
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 6
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 6
- -1 k light chain Proteins 0.000 claims 6
- 108010058905 CD44v6 antigen Proteins 0.000 claims 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 239000013603 viral vector Substances 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 2
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 2
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 claims 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 2
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 108060006580 PRAME Proteins 0.000 claims 2
- 102000036673 PRAME Human genes 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 108010002687 Survivin Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 102100024402 Alpha-1B adrenergic receptor Human genes 0.000 claims 1
- 241000124740 Bocaparvovirus Species 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102000004039 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 1
- 102000003849 Cytochrome P450 Human genes 0.000 claims 1
- 102000015303 Fatty Acid Synthases Human genes 0.000 claims 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 241000701027 Human herpesvirus 6 Species 0.000 claims 1
- 241000829111 Human polyomavirus 1 Species 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 1
- 201000005505 Measles Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000005647 Mumps Diseases 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 102000006601 Thymidine Kinase Human genes 0.000 claims 1
- 108020004440 Thymidine kinase Proteins 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 241000710886 West Nile virus Species 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 208000010805 mumps infectious disease Diseases 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361774040P | 2013-03-07 | 2013-03-07 | |
| US61/774,040 | 2013-03-07 | ||
| PCT/US2014/022137 WO2014138704A1 (en) | 2013-03-07 | 2014-03-07 | Targeting cd138 in cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018176745A Division JP6678215B2 (ja) | 2013-03-07 | 2018-09-21 | がんにおけるｃｄ１３８の標的化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510597A JP2016510597A (ja) | 2016-04-11 |
| JP2016510597A5 true JP2016510597A5 (enExample) | 2017-04-06 |
| JP6409009B2 JP6409009B2 (ja) | 2018-10-17 |
Family
ID=50588798
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561743A Expired - Fee Related JP6409009B2 (ja) | 2013-03-07 | 2014-03-07 | がんにおけるｃｄ１３８の標的化 |
| JP2018176745A Expired - Fee Related JP6678215B2 (ja) | 2013-03-07 | 2018-09-21 | がんにおけるｃｄ１３８の標的化 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018176745A Expired - Fee Related JP6678215B2 (ja) | 2013-03-07 | 2018-09-21 | がんにおけるｃｄ１３８の標的化 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160017048A1 (enExample) |
| EP (3) | EP2964753B1 (enExample) |
| JP (2) | JP6409009B2 (enExample) |
| CN (1) | CN105339498A (enExample) |
| AU (2) | AU2014225365B2 (enExample) |
| CA (1) | CA2904369A1 (enExample) |
| ES (1) | ES2671004T3 (enExample) |
| HK (1) | HK1245841B (enExample) |
| WO (1) | WO2014138704A1 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| SG11201608393TA (en) | 2014-04-10 | 2016-11-29 | Seattle Children S Hospital Dba Seattle Children S Res Inst | Transgene genetic tags and methods of use |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| MX2017000646A (es) | 2014-07-15 | 2017-04-27 | Juno Therapeutics Inc | Celulas geneticamente modificadas para terapia celular adoptiva. |
| BR112017001242A2 (pt) | 2014-07-21 | 2017-12-05 | Novartis Ag | tratamento de câncer usando um receptor antigênico quimérico a cd33 |
| WO2016014565A2 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
| UA123764C2 (uk) | 2014-09-15 | 2021-06-02 | МОЛМЕД СпА | Химерний рецептор антигену та його застосування при лікуванні пухлин, які експресують cd44 |
| AU2015330017A1 (en) * | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| MA40318A (fr) * | 2014-11-05 | 2017-09-13 | Juno Therapeutics Inc | Procédés de transduction et de traitement de cellules |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| IL303543A (en) | 2015-02-18 | 2023-08-01 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| AU2016219785B2 (en) | 2015-02-20 | 2021-10-28 | Ohio State Innovation Foundation | Bivalent antibody directed against NKG2D and tumor associated antigens |
| CA2978171A1 (en) * | 2015-03-10 | 2016-09-15 | J.H. Frederik Falkenburg | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
| WO2016164370A1 (en) * | 2015-04-06 | 2016-10-13 | Ohio State Innovation Foundation | Egfr-directed car therapy for glioblastoma |
| IL254817B2 (en) | 2015-04-08 | 2023-12-01 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell |
| CN108473957B (zh) | 2015-04-17 | 2024-07-16 | 诺华股份有限公司 | 改善嵌合抗原受体表达细胞的功效和扩增的方法 |
| JP6223630B2 (ja) * | 2015-04-17 | 2017-11-01 | 三菱電機株式会社 | 表示制御装置、表示システム、表示制御方法および表示制御プログラム |
| CN113106053A (zh) | 2015-04-21 | 2021-07-13 | 恩立夫克治疗有限责任公司 | 治疗性汇集的血液凋亡细胞制剂与其用途 |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| JP7146632B2 (ja) * | 2015-07-21 | 2022-10-04 | ノバルティス アーゲー | 免疫細胞の有効性および増大を改善する方法 |
| US11458167B2 (en) | 2015-08-07 | 2022-10-04 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
| JP7054924B2 (ja) * | 2015-09-23 | 2022-04-15 | サイトイミューン セラピューティクス， インコーポレイテッド | 免疫療法のためのｆｌｔ３指向ｃａｒ細胞 |
| JP2018536436A (ja) | 2015-12-04 | 2018-12-13 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
| CA3010869A1 (en) * | 2016-01-15 | 2017-07-20 | Etubics Corporation | Methods and compositions for t-cell immunotherapy |
| EP3408297A2 (en) | 2016-01-29 | 2018-12-05 | Med Manor Organics, (P) Ltd | A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof |
| EP3416661A4 (en) * | 2016-02-18 | 2020-03-04 | Enlivex Therapeutics Ltd. | COMBINATION OF IMMUNOTHERAPY AND CYTOKINE CONTROL THERAPY FOR THE TREATMENT OF CANCER |
| WO2017176525A1 (en) * | 2016-04-04 | 2017-10-12 | Promab Biotechnologies, Inc. | Car having replicated binding motifs in a co-stimulatory domain |
| US20190328783A1 (en) * | 2016-04-15 | 2019-10-31 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
| EP3429633B1 (en) | 2016-04-15 | 2021-02-24 | Cellectis | A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation |
| EP3523331A1 (en) | 2016-10-07 | 2019-08-14 | Novartis AG | Chimeric antigen receptors for the treatment of cancer |
| JP7291396B2 (ja) * | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| CA3044682A1 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| KR20190114966A (ko) | 2016-12-09 | 2019-10-10 | 온키뮨 리미티드 | 조작된 자연 살해 세포 및 이의 용도 |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| MX2019011272A (es) | 2017-03-22 | 2019-10-24 | Novartis Ag | Composiciones y metodos para inmunooncologia. |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS |
| SG11201908492PA (en) | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| CN107164412B (zh) * | 2017-06-30 | 2020-10-23 | 山东兴瑞生物科技有限公司 | 一种安全型抗cea嵌合抗原受体修饰t细胞的制备方法及其应用 |
| ES2949855T3 (es) | 2017-12-05 | 2023-10-03 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Linfocitos T que comprenden receptores antigénicos quiméricos anti-CD38 y ant-CD138 y los usos de los mismos |
| WO2019111250A1 (en) * | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising two different chimeric antigen receptors and uses thereof |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| KR20200138741A (ko) | 2018-04-02 | 2020-12-10 | 내셔널 유니버시티 오브 싱가포르 | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 |
| AU2019284911A1 (en) | 2018-06-13 | 2020-12-17 | Novartis Ag | BCMA chimeric antigen receptors and uses thereof |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| WO2020160217A1 (en) * | 2019-02-01 | 2020-08-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Microenvironment sensors to regulate engineered gene expression |
| GB201902277D0 (en) * | 2019-02-19 | 2019-04-03 | King S College London | Therapeutic agents |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| JP7650809B2 (ja) * | 2019-03-06 | 2025-03-25 | レンティジェン・テクノロジー・インコーポレイテッド | 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法 |
| CN111686128A (zh) * | 2019-03-12 | 2020-09-22 | 重庆精准生物技术有限公司 | 一种缺氧可调控的启动子在car-t中的应用 |
| EP3922721A4 (en) * | 2019-03-12 | 2023-01-11 | Chongqing Precision Biotech Company Limited | PROMOTER REGULATED BY HYPOXIA AND ITS APPLICATION |
| CN114945382A (zh) | 2019-11-26 | 2022-08-26 | 诺华股份有限公司 | Cd19和cd22嵌合抗原受体及其用途 |
| KR20220137882A (ko) * | 2019-12-05 | 2022-10-12 | 바이셀릭스, 인크. | 보편적 세포 요법을 위한 면역 회피 기작의 조절제 |
| WO2022072990A1 (en) * | 2020-09-30 | 2022-04-07 | Baylor College Of Medicine | Cytotoxic and costimulatory chimeric antigen receptors |
| BR112023022765A2 (pt) | 2021-05-05 | 2024-01-02 | Immatics Biotechnologies Gmbh | Proteínas de ligação ao antígeno que ligam especificamente o prame |
| WO2025250011A1 (en) | 2024-05-29 | 2025-12-04 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment for cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| GB9304200D0 (en) | 1993-03-02 | 1993-04-21 | Sandoz Ltd | Improvements in or relating to organic compounds |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| GB9810423D0 (en) * | 1998-05-15 | 1998-07-15 | Cancer Res Campaign Tech | Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| JP2011507933A (ja) * | 2007-12-26 | 2011-03-10 | バイオテスト・アクチエンゲゼルシヤフト | 免疫複合体の細胞傷害性副作用の低減及び有効性の改善方法 |
| US9221914B2 (en) * | 2007-12-26 | 2015-12-29 | Biotest Ag | Agents targeting CD138 and uses thereof |
| EP2198884A1 (en) * | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| DK2981607T3 (da) * | 2013-04-03 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller |
-
2014
- 2014-03-07 EP EP14719888.1A patent/EP2964753B1/en active Active
- 2014-03-07 AU AU2014225365A patent/AU2014225365B2/en not_active Ceased
- 2014-03-07 JP JP2015561743A patent/JP6409009B2/ja not_active Expired - Fee Related
- 2014-03-07 WO PCT/US2014/022137 patent/WO2014138704A1/en not_active Ceased
- 2014-03-07 EP EP18190029.1A patent/EP3456818B1/en not_active Not-in-force
- 2014-03-07 CN CN201480026310.9A patent/CN105339498A/zh active Pending
- 2014-03-07 ES ES14719888.1T patent/ES2671004T3/es active Active
- 2014-03-07 CA CA2904369A patent/CA2904369A1/en not_active Abandoned
- 2014-03-07 EP EP17175815.4A patent/EP3241897B1/en active Active
- 2014-03-07 US US14/773,337 patent/US20160017048A1/en not_active Abandoned
-
2016
- 2016-07-11 HK HK18105499.5A patent/HK1245841B/en not_active IP Right Cessation
-
2018
- 2018-09-21 JP JP2018176745A patent/JP6678215B2/ja not_active Expired - Fee Related
-
2019
- 2019-12-09 AU AU2019275678A patent/AU2019275678A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510597A5 (enExample) | ||
| AU2023241321A1 (en) | Bispecific car t-cells for solid tumor targeting | |
| JP6867347B2 (ja) | 免疫療法のためのエンゲージャー細胞 | |
| Zhukovsky et al. | Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection | |
| Ruella et al. | Adoptive immunotherapy for cancer | |
| Zhao et al. | A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity | |
| WO2021129559A1 (zh) | T细胞受体融合蛋白及其用途 | |
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP2018532432A5 (enExample) | ||
| JP2021505131A5 (enExample) | ||
| IL314563A (en) | Non-HLA-restricted T-cell receptors and their uses | |
| RU2017111298A (ru) | Т-КЛЕТКИ С КОСТИМУЛИРУЮЩИМ ХИМЕРНЫМ АНТИГЕННЫМ РЕЦЕПТОРОМ, НАЦЕЛЕННЫЕ НА IL13Rα2 | |
| JP2017536812A5 (enExample) | ||
| RU2018118817A (ru) | Химерные рецепторы антигена, нацеленные на her2 | |
| JP2020530989A5 (enExample) | ||
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| JP2015535689A5 (enExample) | ||
| RU2020133311A (ru) | Иммунотерапия клетками, несущими car и биспецифическое антитело | |
| KR20240018680A (ko) | 혈액 악성종양을 표적으로 하는 키메라 항원 수용체(car), 조성물 및 이의 용도 | |
| JP2017535284A5 (enExample) | ||
| JP2016514457A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| CN112771167A (zh) | 表达有趋化因子的细胞及用途 | |
| IL274806B1 (en) | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof | |
| JP2020501512A5 (enExample) |